The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Global antibiotic use during the COVID-19 pandemic: analysis of pharmaceutical sales data from 71 countries, 2020–2022
Open accessAbstract
Background: Despite bacterial coinfection rates of less than 10%, antibiotics are prescribed to an estimated 75% of patients with COVID-19, potentially exacerbating antimicrobial resistance. We estimated the associations of COVID-19 cases and vaccinations with global antibiotic sales during the first two years of the COVID-19 pandemic. Methods: We obtained monthly data on broad-spectrum antibiotic sales volumes (cephalosporins, penicillins, macrolides, and tetracyclines) in 71 countries during March 2020-May 2022 from the IQVIA MIDAS® database. These data were combined with country-month-level COVID-19 case and vaccination data from Our World in Data. We used least squares (pooled) and fixed-effects panel data regression models, accounting for country characteristics, to estimate the associations between antibiotic sales volumes and COVID-19 cases and vaccinations per 1000 people. Findings: Sales of all four antibiotics fell sharply during April and May 2020, followed by a gradual rise to near pre-pandemic levels through May 2022. In fixed-effects regression models, a 10% increase in monthly COVID-19 cases was associated with 0.2%-0.3% higher sales of cephalosporins, 0.2%-0.3% higher sales of penicillins, 0.4%-0.6% higher sales of macrolides, and 0.3% higher sales of all four antibiotics combined per 1000 people. Across continents, a 10% increase in monthly COVID-19 cases was associated with 0.8%, 1.3%, and 1.5% higher macrolides sales in Europe, North America, and Africa respectively. Sales of other antibiotics across continent were also positively associated with COVID-19 cases, although the estimated associations were smaller in magnitude. No consistent associations were observed between antibiotic sales and COVID-19 vaccinations. Results from pooled regression analysis were similar to those from the fixed-effects models. Interpretation: Antibiotic sales were positively associated with COVID-19 cases globally during 2020-2022. Our findings underline that antibiotic stewardship in the context of COVID-19 remains essential. Funding: Bill & Melinda Gates Foundation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis
Murray, C. J. L., Ikuta, K. S., Sharara, F., Swetschinski, L., Robles Aguilar, G., Gray, A., Han, C., Bisignano, C., Rao, P., Wool, E., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(21)02724-0 · Cited by 16,316
An interactive web-based dashboard to track COVID-19 in real time
Dong, E., Du, H., & Gardner, L. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30120-1 · Cited by 10,048
Global increase and geographic convergence in antibiotic consumption between 2000 and 2015
Klein, E. Y., Van Boeckel, T. P., Martinez, E. M., Pant, S., Gandra, S., Levin, S. A., Goossens, H., & Laxminarayan, R. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1717295115 · Cited by 3,232
Llor, C., & Bjerrum, L. (2014) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098614554919 · Cited by 2,079
Antimicrobial Resistance: Implications and Costs
Dadgostar, P. (2019) · Infection and Drug Resistance · doi:10.2147/idr.s234610 · Cited by 2,024
Bell, B. G., Schellevis, F., Stobberingh, E., Goossens, H., & Pringle, M. (2014) · BMC Infectious Diseases · doi:10.1186/1471-2334-14-13 · Cited by 1,262
Klein, E. Y., Milkowska-Shibata, M., Tseng, K. K., Sharland, M., Gandra, S., Pulcini, C., & Laxminarayan, R. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30332-7 · Cited by 500
Causey, K., Fullman, N., Sorensen, R. J. D., Galles, N. C., Zheng, P., Aravkin, A., Danovaro-Holliday, M. C., Martinez-Piedra, R., Sodha, S. V., Velandia-González, M. P., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01337-4 · Cited by 450
Immunological characteristics govern the transition of COVID-19 to endemicity
Lavine, J. S., Bjornstad, O. N., & Antia, R. (2021) · Science · doi:10.1126/science.abe6522 · Cited by 416
Shet, A., Carr, K., Danovaro-Holliday, M. C., Sodha, S. V., Prosperi, C., Wunderlich, J., Wonodi, C., Reynolds, H. W., Mirza, I., Gacic-Dobo, M., et al. (2022) · The Lancet Global Health · doi:10.1016/s2214-109x(21)00512-x · Cited by 363 · cited 1×
“29 – 32 Understanding the systemic effect of the pandemic on overall antibiotic use given these counteracting factors is important for developing antimicrobial stewardship programs for COVID-19.”
Cited by
Antimicrobial Resistance (AMR)
Tang, K. W. K., Millar, B. C., & Moore, J. E. (2023) · British Journal of Biomedical Science · doi:10.3389/bjbs.2023.11387 · Cited by 1,009
Global trends in antibiotic consumption during 2016–2023 and future projections through 2030
Klein, E. Y., Impalli, I., Poleon, S., Denoel, P., Cipriano, M., Van Boeckel, T. P., Pecetta, S., Bloom, D. E., & Nandi, A. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2411919121 · Cited by 436
Self-citation
Metadata
- Authors
- Nandi, A., Pecetta, S., & Bloom, D. E.
- Venue
- eClinicalMedicine
- Publisher
- Elsevier BV
- Published
- 2023-03
- Volume
- 57
- Pages
- 101848
- ISSN
- 2589-5370 (ISSN-L)
- OpenAlex
- W4320475034
- Cited by
- 220
- References
- 14
- FWCI
- 30.65
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Global antibiotic use during the COVID-19 pandemic: analysis of pharmaceutical sales data from 71 countries, 2020–2022. https://app.cochat.ai/papers/10.1016/j.eclinm.2023.101848
- The paper
- Nandi, A., Pecetta, S., & Bloom, D. E. (2023). Global antibiotic use during the COVID-19 pandemic: analysis of pharmaceutical sales data from 71 countries, 2020–2022. eClinicalMedicine. https://doi.org/10.1016/j.eclinm.2023.101848
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.